Streetbeat News

MYNZ

Mainz Biomed B.V.

Industry

Medical - Diagnostics & Research

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Open

0.25

Mkt cap

5.2M

Volume

2.6M

High

0.25

P/E Ratio

-0.22

52-wk high

1.79

Low

0.23

Div yield

N/A

52-wk low

0.18

Mainz Biomed reported a revenue of $0.52 million for the first half of 2024, marking a 4% increase year-over-year. However, the company also reported an EPS loss of $(0.49).

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:06 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included Gritstone Bio, Hoth Therapeutics, Lipella Pharmaceuticals, Enveric Biosciences, Oncternal Therapeutics, and Chemomab Therapeutics. Losers included Virpax Pharmaceuticals, Burning Rock Biotech, Mainz Biomed, CareDx, Inventiva, and Novo Integrated Sciences.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 12:08 pm

Several health care stocks experienced significant intraday movements on Monday. Notable gainers included Tevogen Bio Holdings, INVO Bioscience, and Longboard Pharmaceuticals, while Molecular Templates and Trinity Biotech were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 4:30 pm

Pharmaceutical companies are focusing on personalized cancer therapies and immunotherapy as new strategies against cancer. Pfizer and Moderna are investing in mRNA technology for cancer treatment, while Merck has shown success with its Keytruda treatment. Mainz Biomed is advancing early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

October 10, 2024 | 6:00 pm

Mainz Biomed has reported a rise in demand from both current and potential laboratory partners for its improved Coloalert product, which is used for colorectal cancer screening.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 12:10 pm

Several healthcare stocks experienced significant price movements in Monday's after-market session. Vincerx Pharma, Oragenics, Avidity Biosciences, Tivic Health Systems, Verrica Pharmaceuticals, and Immunome saw gains, while LogicMark, Trevena, Soligenix, Mainz Biomed, Kairos Pharma, and Cue Biopharma experienced declines.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 8:31 pm

Pfizer and Moderna are leveraging mRNA technology, initially successful in COVID-19 vaccines, to target cancer treatment. Pfizer is focusing on oncology with a $43 billion acquisition of Seagen, while Moderna collaborates with Merck on cancer trials. Mainz Biomed is advancing early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

October 01, 2024 | 6:11 pm

Mainz Biomed N.V. (NASDAQ:MYNZ) released a statement outlining its strategic plans for growth, including a significant FDA trial in 2025 aimed at entering the U.S. market. The company anticipates substantial growth through its innovative cancer diagnostic solutions.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 12:10 pm

Several health care stocks experienced significant price movements during Friday's intraday session. Onconetix, Cue Biopharma, Plus Therapeutics, Estrella Immunopharma, Indaptus Therapeutics, and Mainz Biomed saw notable gains, while Theriva Biologics, enVVeno Medical, Inspire Veterinary, Palatin Techs, Acadia Healthcare, and Impact BioMedical experienced declines.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.